GEN Exclusives

More »

GEN News Highlights

More »
Feb 7, 2012

Brooks Life Science, Scripps Research to Work on Microplate Imaging System

  • Brooks Life Science Systems has initiated a technology development and commercialization partnership with The Scripps Research Institute. The deal includes an exclusive license to jointly complete the development of a microplate imaging system created by Scripps Research and to enable Brooks Life Science Systems to manufacture and commercialize this imaging system.

    The new Brooks Plate Auditor™ is being developed for compound management and high-throughput screening (HTS). “This technology was developed to address an unmet need in our compound management operation—the automated assessment of compound quality in plate-based HTS libraries,” explains Peter Hodder, Ph.D., senior director and head of lead identification at the Florida campus of Scripps Research. “Both HTS and compound management staff now consider it indispensable for routine quality control of cherry-picked samples as well as periodic monitoring of sample quality across all our screening libraries.”

    John Lillig, svp and managing director of Brooks Life Science Systems, notes, “With over 350 million samples stored in Brooks Sample Management Systems around the world, the new Plate Auditor will complement our Brooks Tube Auditor and be a valuable new quality enhancement tool for our compound management customers.”

    Scripps Research presented the technology in a talk entitled “A Novel Platform to Improve HTS Compound Management Operations” at the Society for Laboratory Automation and Screening conference in San Diego on Monday, February 6.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »